BIMINI Biotech Secures €3 Million to Advance Novel Hematological Cancer Treatments
Leiden-based BIMINI Biotech has announced the successful completion of a €3 million seed funding round aimed at propelling its research and development efforts in innovative therapeutics for hematological cancers. The funding round was led by Torrey Pines Investment (TPI), based in San Diego, with additional support from InnovationQuarter Capital (IQC), Libertatis Ergo Holding (LEH), and a business angel.

Leiden-based BIMINI Biotech has announced the successful completion of a €3 million seed funding round aimed at propelling its research and development efforts in innovative therapeutics for hematological cancers. The funding round was led by Torrey Pines Investment (TPI), based in San Diego, with additional support from InnovationQuarter Capital (IQC), Libertatis Ergo Holding (LEH), and a business angel.
The funding provides critical resources for BIMINI Biotech to advance its preclinical programs and expand its proprietary drug discovery platform. Speaking on the milestone, Dr. Digvijay Gahtory, CEO of BIMINI Biotech, emphasized, “We are excited to welcome this experienced group of investors and have the continued support of our existing shareholders that believe in the potential of our first-in-class WASp-modulators.”
Founded in 2019, the company focuses on developing small molecule therapeutics targeting lymphomas and leukemias, two forms of cancer with significant unmet medical needs. BIMINI Biotech’s research centers on a novel mechanism of action involving the Wiskott Aldrich Syndrome Protein (WASp), a protein exclusively expressed in hematopoietic cells. WASp has been linked to the aggressiveness of hematological tumors, and the company’s WASp modulators have demonstrated promising anti-cancer effects in both in vitro and in vivo studies.
The unique approach taken by BIMINI Biotech aims to fill a critical gap in the treatment landscape for hematological cancers. Current therapies often fall short, especially in aggressive subtypes of lymphoma and leukemia, where relapse rates remain high, and many patients face limited treatment options. Commenting on this challenge, Dr. Maurits van den Nieuwboer, COO of BIMINI Biotech, noted, “For aggressive leukemia and lymphoma subtypes, it is not a matter ‘if’ patients relapse, but ‘when’ patients relapse. As such, there is still a dire need for novel therapeutic strategies. BIMINI Biotech can fill this gap.”
The newly secured funding will accelerate the development of BIMINI Biotech’s WASp modulators, focusing on validating their preclinical safety and efficacy. The company’s work will be supported by Expert Systems, an AI-driven accelerator platform that aids in preclinical drug discovery and early development. This advanced platform integrates computational drug design with cutting-edge research expertise, providing BIMINI Biotech with a robust framework for innovation.
The investment round also reflects the growing interest of global investors in high-impact research areas such as hematology. Rouslan Michtchenko, Director of Strategic Partnering and Investment at TPI, stated, “We are very pleased to support the team and exciting science behind BIMINI Biotech and see this European investment as another milestone of our strategic expansion in such high-impact research areas as hematology.”
The significance of this work is underscored by the challenges faced by elderly patients with comorbidities, who often cannot undergo intensive therapies or cell-based treatments. With limited alternatives available, the need for new, targeted therapies with novel mechanisms of action is more pressing than ever. BIMINI Biotech’s approach offers hope for improved outcomes, potentially transforming the treatment paradigm for hematological cancers.
Expressing confidence in the team, Linn Backegren-van Ingen, Investment Manager at IQC, remarked, “We are impressed by the dedication and expertise of the BIMINI team and look forward to seeing them take the next steps in this important journey. Therefore, we are excited to support BIMINI Biotech in their mission to improve outcomes for leukemia and lymphoma patients.”
With its innovative research and strategic investment, BIMINI Biotech is poised to make meaningful strides in addressing the unmet needs of hematological cancer patients worldwide.